Neurotransmitter interactions in schizophrenia-therapeutic implications A. CarlssonNicholas WatersMaria L. Carlsson Pages: S37 - S43
The role of immune function in schizophrenia: an overview N. MüllerMicheal RiedelMarkus J. Schwarz Pages: S62 - S68
Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia S. KasperJ. TauscherS. Quiner Pages: S83 - S89
Developmental malformations in cerebral structures of schizophrenic patients H. Beckmann Pages: S44 - S47
Family and genetic studies on the relationship of schizophrenia to affective disorders W. MaierMarcella RietschelDieter B. Wildenauer Pages: S57 - S61
The neuropathology of schizophrenic diseases: historical aspects and present knowledge B. Bogerts Pages: S2 - S13
Principles and results of family therapy in schizophrenia Kurt HahlwegGeorg Wiedemann Pages: S108 - S115
Atypical neuroleptics: a new approach in the treatment of negative symptoms Hans-Jürgen Möller Pages: S99 - S107
The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies H. HäfnerW. an der Heiden Pages: S14 - S26
Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: preliminary results of a follow-up study R. BottlenderUlrike WegnerHans-Jürgen Möller Pages: S27 - S36
Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs J. IchikawaHerbert Y. Meltzer Pages: S90 - S98
Cognitive dysfunction in schizophrenia: unifying basic research and clinical aspects R. W. McCarleyM. A. NiznikiewiczMartha E. Shenton Pages: S69 - S82
